# TELA earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/TELA) · [Earnings tab](https://www.lopjlb.com/stock/TELA?tab=earnings) Updated: 2026-08-10T05:09:45 Quarters analyzed: 8 ## Cross-quarter narrative Across eight quarterly call summaries, TELA Bio moved from modest, uncertain guidance in 2024 to a pattern of accelerating revenue and expanding commercial reach by mid‑2026. After a strong Q3 2024 rebound, Q4 2024 highlighted weather‑related setbacks and headcount loss, prompting a revised commercial strategy and new product launches. 2025 saw a series of restructurings—TM/AS model, patient‑centric sales, and a fully staffed U.S. force—paired with record revenue growth, NHS England framework agreement, and a shift toward OviTex units while PRS sales softened. Guidance was raised in FY25 and then held steady, while balance‑sheet actions (equity raise, debt upsizing) reinforced financial flexibility. Storm disruptions re‑emerged in Q4 2025, introducing short‑term uncertainty, but the company continued to launch products (OviTex LTR, LiquiFix) and advance clinical trials. By Q1 2026, international sales surged, the sales organization was fully staffed, and guidance remained ≥8% growth, indicating a transition from reactive adjustments to a more disciplined, growth‑oriented trajectory. ## Latest CallCard · Q1 TELA Bio Q1 2026: Revenue $19.1M (+3% YoY), international +41%, OviTex units +16%; fully staffed US sales force, OviTex LTR launched, Board refreshed; guidance maintained ≥8% growth, Q2 ~$20M.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Prepared remarks emphasize fully staffed commercial team, OviTex **Guidance:** vague **Tone:** mgmt 0 · Q&A pressure 0 · divergence 0 ## Quarter one-liners - **2026 Q1:** TELA Bio Q1 2026: Revenue $19.1M (+3% YoY), international +41%, OviTex units +16%; fully staffed US sales force, OviTex LTR launched, Board refreshed; guidance maintained ≥8% growth, Q2 ~$20M.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Prepared remarks emphasize fully staffed commercial team, OviTex - **2025 Q4:** TELA Bio reports 16% revenue growth in 2025, record Q4 sales, and a revamped commercial team, while flagging new rep ramp‑up and storm‑related procedure delays as near‑term uncertainties. - **2025 Q3:** TELA Bio Q3 2025: revenue $20.7M (+9% YoY), 3rd straight quarter of sequential growth; FY25 guidance raised to ≥16% YoY, FY26 directional ≥15%; balance sheet strengthened via $60M debt upsize + $13M equity (~$26M net cash); commercial org revamped with 76 territory managers, Liquefix partnership +12 - **2025 Q2:** TELA Bio Q2 revenue hits $20.2M (+26% YoY), first quarter >$20M; reiterates $78-82M FY guidance; PRS +53%, OviTex +12%; NHS England framework deal; shifting to patient-centric commercial model.','tone': {'mgmt': 0.6, 'mgmt_rationale': 'Prepared remarks highlight record revenue, strong unit growth ac - **2025 Q1:** TELA Bio Q1 2025: $18.5M revenue (+12% YoY), reaffirmed $85-88M full-year guidance (23-27% growth), commercial restructuring with TM/AS model showing traction, tariff impact 50-100 bps on gross margin, OviTex unit sales +29%, PRS unit sales -3% but revenue up on ASP. European growth 17%. Cash $42.8M - **2024 Q4:** TELA Bio’s Q4 2024 revenue was $17.6 M, a modest 3.8% growth, with underperformance driven by sales‑force headcount loss and a hurricane, while management is upbeat on 2025 thanks to a revised commercial strategy, new product traction and pipeline growth. - **2024 Q3:** TELA Bio delivered strong Q3 with 26% YoY revenue growth to $19M, unit sales up 39-44%, Europe 67% growth, $43M equity raise, $5-10M annualized OpEx savings, and maintained 28-31% full-year guidance.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Management highlighted strong Q3 results, return to histor - **2024 Q2:** — ## Theme arcs - **Revenue growth trajectory** (improving): From modest 3.8% Q4 2024 growth to consistent double‑digit YoY increases and FY guidance upgrades. - **Commercial organization restructuring** (improving): Implementation of Account Specialists, TM/AS model, expanded territory managers, and full U.S. staffing. - **Product portfolio dynamics** (improving): OviTex unit sales rose steadily; PRS sales softened but revenue held via higher ASP. - **External weather disruptions** (stable): Hurricane Helene (2024) and East Coast storms (2025) caused procedural delays in two quarters. - **Margin pressure and discipline** (improving): Early inventory write‑offs and tariff impacts gave way to spending discipline and expected margin improvement. - **Capital structure strengthening** (improving): Equity raise in 2024, debt upsizing in 2025, and net cash buildup support growth. - **Guidance consistency** (stable): Guidance maintained through 2024‑2025, raised in FY25, then held steady in 2026. - **International expansion** (improving): European growth in 2025 and 41% international revenue increase in Q1 2026. - **Strategic partnerships** (new): NHS England framework deal and LiquiFix partnership introduced in 2025. ## Fear persistence - **Headcount attrition and competitive poaching** [resolved]: Raised in Q4 2024 but not referenced in later calls. - **Weather‑related disruptions** [recurring]: Hurricane Helene (2024) and East Coast storms (2025) caused procedural delays. - **Seasonal demand softness** [resolved]: Mentioned only in Q4 2024. - **Inventory obsolescence** [resolved]: Cited as margin pressure in Q4 2024 only. - **New rep productivity lag** [new]: Identified as near‑term uncertainty in Q4 2025. - **OviTex vs PRS mix uncertainty** [new]: Analyst concern raised in Q4 2025. - **European pricing dynamics** [new]: Potential margin impact noted in Q4 2025. - **AMS partnership reliance** [new]: Growth of LiquiFix and academic program tied to AMS support in Q4 2025. ## Guidance path 2024 Q2:vague → 2024 Q3:vague → 2024 Q4:maintained → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:vague → 2025 Q4:raised → 2026 Q1:vague --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/TELA`